Loading organizations...
§ Private Profile · San Jose, CA, USA
Biotechnology company developing cellular reprogramming technology to create new hair follicles for hair loss, focused on regenerative medicine.
dNovo Bio has raised $3.0M across 1 funding round.
Key people at dNovo Bio.
dNovo Bio was founded in 2018 by Ernesto Lujan (Founder).
dNovo Bio has raised $3.0M in total across 1 funding round.
Based in San Jose, California, dNovo Bio is a biotechnology company developing cellular reprogramming technology to generate new hair follicles for the treatment of severe hair loss. The enterprise utilizes patent-pending methods to convert standard patient cells into specialized dermal papilla cells, successfully demonstrating the clinical ability to grow reprogrammed human hair on laboratory mice. Backed by the prominent startup accelerator Y Combinator, the privately held regenerative medicine firm has raised $2.7 million in seed funding and currently operates with a highly specialized core team of four employees. The company's scientific staff includes medical doctors and researchers with advanced genetics degrees from Stanford, Harvard, and Caltech, who aim to eventually expand this direct reprogramming approach to regenerate other complex human tissues and organs on demand. dNovo Bio was founded in 2018 by Ernesto Lujan.
dNovo Bio was founded in 2018 by Ernesto Lujan (Founder).
dNovo Bio has raised $3.0M in total across 1 funding round.
dNovo Bio's investors include Addition, Alchemy Ventures, Alloy Fund, Adeyemi Ajao, B Capital Group, Broadhaven Capital Partners, Felicis Ventures, First Round Capital, Founders Fund, General Catalyst, Lightspeed Venture Partners, LocalGlobe.
dNovo Bio has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in January 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2022 | $3M Seed | — | Addition, Alchemy Ventures, Alloy Fund, Adeyemi Ajao, B Capital Group, Broadhaven Capital Partners, Felicis Ventures, First Round Capital, Founders Fund, General Catalyst, Lightspeed Venture Partners, LocalGlobe, Monashees, Mouro Capital, Okta Ventures, Operator Partners, ParaFi Capital, Pareto Holdings, Picus Capital, Sarona Ventures, Softbank Latin America Fund, Soma Capital, The HIT Forge, Tiger Global Management, Webb Investment Network, Xochi Ventures, Y Combinator, Anthony Pompliano, Justin Mateen, Mike Krieger, Ricardo Weder, Roger Laughlin Carvallo, Sean Behr, Teddy Citrin, Charlie Songhurst, Claudio Pinkus, Jason Hodges, Jean Pigozzi, Joey Krug, MAX Kolysh, Paul Buchheit, Ataria Ventures, Duro Ventures, Pioneer Fund, Testmunk, Yintai Investment Company | Announced |
Key people at dNovo Bio.
dNovo Bio is a pre-clinical cell technology company developing a proprietary direct reprogramming system to generate personalized stem cells from patient-derived cells like skin, blood, or fat, initially targeting hair loss as a cure for baldness by creating new hair stem cells *de novo*.[1][2][4] The company serves individuals suffering from age-related or condition-induced hair loss, such as male pattern baldness, by addressing the root cause—depletion of functional hair stem cells—rather than merely slowing or masking it.[1][5] Its technology converts skin cells directly into induced hair stem cells without a pluripotent state, proven to produce hair in mouse models, with broader ambitions to combat aging by replenishing lost stem cells.[1][2]
Founded in 2018 with Y Combinator support, dNovo emerged from stealth in 2022, showcasing proof-of-principle results and seeking partners for advancement; it operates from Silicon Valley, emphasizing scalability and speed in its approach.[1][5]
dNovo was founded in 2018 by Dr. Ernesto Lujan, a scientist whose expertise in direct reprogramming drove the company's inception.[1] Lujan, now CEO, developed the core idea of converting human skin cells into hair stem cells to treat baldness, inspired by the need to regenerate depleted stem cells lost to aging or conditions like male pattern baldness.[1][2]
The company launched with initial backing from Y Combinator, remaining in stealth until early 2022, when it publicly demonstrated its technology's feasibility: generating induced human hair stem cells that grew hair in mice.[1] This pivotal reveal highlighted the system's advantages—quicker and more scalable than pluripotent methods—and positioned dNovo for partnerships, such as potential ties with Takeda Pharmaceutical.[1]
dNovo rides the wave of cellular reprogramming and regenerative medicine, a trend accelerating with advances in stem cell tech to reverse aging effects like tissue degeneration.[2] Timing aligns with surging demand for hair loss solutions—affecting millions—amid limitations of existing treatments (e.g., minoxidil, transplants), as market forces favor curative biotech over symptom management.[1][5]
In Silicon Valley's biotech hub, dNovo influences the ecosystem by validating direct reprogramming for consumer-facing applications, potentially inspiring scalable therapies for skin, organs, or age-related diseases; its Y Combinator roots amplify network effects for funding and partnerships in a post-stealth phase ripe for clinical translation.[1][5]
dNovo's near-term path involves platform optimization, partner collaborations (e.g., pharma like Takeda), and preclinical-to-clinical transitions for hair loss therapies, leveraging mouse data toward human trials.[1] Broader trends in anti-aging biotech—personalized stem cell manufacturing and AI-aided reprogramming—will propel expansion beyond baldness to systemic rejuvenation.[2]
As influence grows, dNovo could redefine accessible cures for aging's visible hallmarks, evolving from stealth hair innovator to stem cell platform leader, delivering *de novo* regeneration to millions.
